Tobias Kiesslich
Salzburg, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 110 publications
Emerging claudin-18.2 antagonists in the treatment of biliary tract cancer.
Journal: Expert opinion on emerging drugs
Published: June 03, 2026
Uric acid and subclinical atherosclerosis: distinct associations across coronary and carotid arteries.
Journal: Clinical research in cardiology : official journal of the German Cardiac Society
Published: April 15, 2026
The Use of Body Mass Index Polygenic Risk Score (BMI-PRS) in a Paediatric Population With Obesity.
Journal: Pediatric obesity
Published: January 31, 2026
Translating Fibrosis to Malignancy: Biomarkers and Therapeutic Opportunities in Liver Fibrosis and Hepatocellular Carcinoma.
Journal: Medical sciences (Basel, Switzerland)
Published: January 07, 2026
Clinical Endoscopic Submucosal Dissection of Trainees Tutored by Experts-ESGE Endorsed Courses and Live Endoscopic Events 2011-2015.
Journal: Journal of clinical medicine
Published: November 25, 2025
New frontiers in the pharmacological management of biliary tract carcinomas: the emerging role of drug conjugates.
Journal: Expert opinion on pharmacotherapy
Published: April 17, 2025
The importance of preclinical models for cholangiocarcinoma drug discovery.
Journal: Expert opinion on drug discovery
Published: January 22, 2025
The Cdk inhibitor dinaciclib as a promising anti-tumorigenic agent in biliary tract cancer.
Journal: Cancer biology & therapy
Published: December 13, 2024
Assessing the role of polygenic risk scores in cardiovascular risk prediction: a cross-sectional analysis from the Paracelsus 10 000 cohort.
Journal: European journal of preventive cardiology
Published: December 03, 2024
The efficacy of ferroptosis-inducing compounds IKE and RSL3 correlates with the expression of ferroptotic pathway regulators CD71 and SLC7A11 in biliary tract cancer cells.
Journal: PloS one
Published: February 05, 2024
Editorial: Novel therapeutic approaches for biliary tract cancer and hepatocellular carcinoma.
Journal: Frontiers in cell and developmental biology
Published: October 11, 2023
New insights into possible HDAC inhibitor resistance in DLBCL - Comment on 'defining cellular responses to HDAC-selective inhibitors reveals that efficient targeting of HDAC3 is required to elicit cytotoxicity and overcome naïve resistance to pan-HDACi in diffuse large B cell lymphoma' by Havas et al.
Journal: Translational oncology
Published: October 03, 2023
Last Updated: 09/26/2026